The Neurobiology and Treatment of Restless Legs Syndrome

Background: Restless legs syndrome (RLS) is a relatively common neurological disorder affecting sleep and health-related quality of life. Neuroimaging studies, autopsy investigations and experimental studies using animal models have been conducted to investigate the potential causes of RLS, resulting in the generation of multiple pathophysiological hypotheses. Methods: This paper reviews the neurobiology and pharmacotherapy of RLS, with a critical analysis of the heterogeneity and methodological limitations of the existing scientific literature. Results: Although several neurotransmitter systems dysfunction and neuroanatomical abnormalities have been implicated in RLS pathogenesis, dopamine dysfunction within basal ganglia pathways, iron deficiency and opioid system abnormalities have consistently been found to be involved. Their involvement is further strengthened by the therapeutic effectiveness of dopaminergic agents, iron supplementation and opioid medications. Discussion: Converging evidence from neuroimaging, autoptic and animal studies points towards dopamine dysregulation and iron metabolism alterations as the main contributors to RLS pathophysiology. The possible interactions between different neurotransmitter systems should guide further neuropharmacological research in order to improve therapeutic efficacy for this disabling condition.

• Publication year

  2013

• Venue

  Behavioural Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3233/BEN-2012-120271PMID 22713426PMCID 5214985
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis

  2014cited by this paper
• The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.

  2012cited by this paper
• Profile of altered brain iron acquisition in restless legs syndrome.

  2011cited by this paper
• Gabapentin Enacarbil: Pharmacotherapy of Restless Legs Syndrome

  2010cited by this paper
• [Pathophysiology of restless legs syndrome].

  2010cited by this paper
• Update in restless legs syndrome.

  2010influential reference
• Restless Legs Syndrome

  2010cited by this paper
• Restless legs syndrome: pathophysiology, clinical presentation and management

  2010cited by this paper
• Gabapentin enacarbil – clinical efficacy in restless legs syndrome

  2010cited by this paper
• Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study.

  2009cited by this paper
• The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal.

  2009cited by this paper
• Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome.

  2009cited by this paper
• Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis.

  2009cited by this paper
• Restless legs syndrome: pathophysiology and the role of iron and folate.

  2007cited by this paper
• Restless legs syndrome: a clinical update.

  2006influential reference
• Considering the causes of RLS

  2006cited by this paper
• Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.

  2006cited by this paper
• MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome.

  2006cited by this paper
• Circadian changes in CSF dopaminergic measures in restless legs syndrome.

  2006cited by this paper
• The restless legs syndrome.

  2005cited by this paper
• The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study.

  2005cited by this paper
• CSF iron, ferritin and transferrin levels in restless legs syndrome

  2005cited by this paper
• Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome

  2005cited by this paper
• Noctural myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration

  2005cited by this paper
• The restless legs syndrome.

  2005cited by this paper
• Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome

  2004cited by this paper
• Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome.

  2004cited by this paper
• Functional neuroimaging studies in restless legs syndrome.

  2004cited by this paper
• Why do restless legs occur at rest?--pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2).

  2004cited by this paper
• An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.

  2004cited by this paper
• Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients

  2004cited by this paper
• Restless legs syndrome

  2003cited by this paper
• Clinical practice. Restless legs syndrome.

  2003cited by this paper
• Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome

  2003cited by this paper
• SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep

  2002influential reference
• Principles and Practice of Sleep Medicine

  2001cited by this paper
• Restless Legs Syndrome: A Review of Clinical and Pathophysiologic Features

  2001cited by this paper
• Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome

  2001cited by this paper
• Normal IPT and IBZM SPECT in drug naive and levodopa-treated idiopathic restless legs syndrome.

  2001cited by this paper
• No induction of apoptosis by IFN-β in human antigen-specific T cells

  2000cited by this paper
• Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome

  2000cited by this paper
• Clinical correlates of 6‐hydroxydopamine injections into A11 dopaminergic neurons in rats: A possible model for restless legs syndrome?

  2000cited by this paper
• Striatal dopaminergic function in restless legs syndrome

  1999cited by this paper
• Positron emission tomographic studies in restless legs syndrome

  1999cited by this paper
• The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review.

  1999cited by this paper
• Abnormal rat brain monoamine metabolism in iron deficiency anemia

  1995cited by this paper
• The neurobiology of disease

  1990cited by this paper
• Dyskinesias while awake and periodic movements in sleep in restless legs syndrome

  1986cited by this paper
• Dominantly inherited restless legs with myoclonus and periodic movements of sleep: a syndrome related to the endogenous opiates?

  1986cited by this paper
• Treatment of restless legs syndrome with levodopa plus benserazide.

  1982cited by this paper

• Microstructural changes of basal ganglia in migraine with restless legs syndrome: findings from a neuroimaging study

  2022cites this paper
• Progressive Pontine-Medullary Dysfunction Leads to REM Sleep Behavior Disorder Symptoms in a Chronic Model of Parkinson’s Disease

  2021cites this paper
• Liver disease severity is poorly related to the presence of restless leg syndrome in patients with cirrhosis

  2019influential citation
• Risk factors for restless legs syndrome in hemodialysis patients in Taiwan

  2019cites this paper
• Neuropsychiatry for the Twenty-First Century

  2018cites this paper
• Circadian-based Treatment Strategy Effective in the BACHD Mouse Model of Huntington’s Disease

  2018cites this paper
• Prevalence of restless legs symptoms according to depressive symptoms and depression type: a cross-sectional study

  2018cites this paper
• Targeted disruption of supraspinal motor circuitry reveals a distributed network underlying Restless Legs Syndrome (RLS)-like movements in the rat

  2017cites this paper
• ‘Cycling’ with long‐acting dopamine agonists for augmentation in restless legs syndrome

  2016cites this paper
• Prevalence, severity, and impact on quality of life of restless leg syndrome in patients with liver cirrhosis in India

  2016cites this paper
• The Prevalence of Fibromyalgia in Patients with Restless Legs Syndrome

  2016cites this paper
• Transcranial direct current stimulation on primary sensorimotor area has no effect in patients with drug-naïve restless legs syndrome: a proof-of-concept clinical trial.

  2015cites this paper
• Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome

  2015cites this paper
• Sleep and Sleep–Wake Disorders

  2015cites this paper
• Mood disorders in restless legs syndrome (Willis-Ekbom disease).

  2014cites this paper
• Preclinical evidence supporting the clinical development of central pattern generator-modulating therapies for chronic spinal cord-injured patients

  2014cites this paper
• [Prevalence of restless legs syndrome in 69,830 Mexican women].

  2014cites this paper
• Prevalencia del síndrome de piernas inquietas en 69,830 mujeres mexicanas

  2014cites this paper
• Central Pattern Generator for Locomotion: Anatomical, Physiological, and Pathophysiological Considerations

  2013cites this paper